City of Hope

Latest from City of Hope

Phase 1 Study in R/R Hodgkin Lymphoma Shows Significant Responses to Pembrolizumab Plus Oral Vorinostat

January 04, 2022

In preclinical studies, HDAC inhibitors have been shown to have immunomodulatory effects— including enhancing antigen presentation, recruiting T cells into tumors, and promoting T-cell function—when combined with PD-1 inhibitors.

Panel Discusses the Ongoing Evolution of Remote Patient Care

December 19, 2021

The discussion, "Remote Patient Monitoring: Case Studies From the Front Lines,” explored real-world experiences with technology that has taken on greater heft as the COVID-19 pandemic continues to affect health care delivery.

PCOC SPOTLIGHT: Empowering Stakeholders Across the Breadth of Oncology

December 19, 2021

Joseph Alvarnas, MD, a co-chair of Patient-Centered Oncology Care® (PCOC), discussed the unique nature of PCOC and what it offers for providers, payers, policy leaders, and technology experts who take part. Alvarnas is vice president, Government Affairs; senior medical director, employer strategy, and clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope.

Dr L. Elizabeth Budde: Mosunetuzumab Is Effective, Well Tolerated in R/R FL

December 11, 2021

L. Elizabeth Budde, MD, PhD, oncologist and associate professor at City of Hope, discusses the use of mosunetuzumab in patients with relapsed/refractory follicular lymphoma (R/R FL) who have received 2 or more prior lines of therapy and addresses potential cost-related implications of the drug compared with CAR T-cell therapy.

What We’re Reading: Pfizer Says Omicron May Require Fourth Dose; CMS Shares ACA Enrollment Figures; City of Hope Makes Acquisition

December 09, 2021

Pfizer predicts that a fourth dose of a COVID-19 vaccine may be needed to quell the Omicron variant; CMS officials share figures on enrollment for health coverage under the Affordable Care Act (ACA); City of Hope announces acquisition of Cancer Treatment Centers of America.

City of Hope’s Tingting Tan, MD, PhD, on the Changing SCLC Landscape: “There’s Always Reason to Be Hopeful”

October 27, 2021

Tingting Tan, MD, PhD, a medical oncologist and lung cancer specialist at City of Hope, is an expert in molecular signaling pathways in tumor development and the mechanisms of chemotherapy resistance. She discussed how the treatment landscape in small cell lung cancer has shifted in the past 5 years, offering much more hope for patients.